Stay updated on Atrasentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Atrasentan in IgA Nephropathy Clinical Trial page
- CheckyesterdayChange DetectedAdds a recruitment status note indicating the trial is no longer recruiting participants and includes new navigation items such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study'; removes the old 'Intervention / Treatment' label in favor of 'Intervention/Treatment' and adds the site revision note 'Revision: v3.6.0'.SummaryDifference0.2%

- Check8 days agoChange DetectedNovartis Pharmaceuticals is now listed as sponsor with new identifiers and drug details added. The study plan now includes an open-label atrasentan extension, a zigakibart substudy, and updated timelines including primary completion in 2028-04-14 and enrollment of 404 participants.SummaryDifference2%

- Check16 days agoChange DetectedA new publication citation was added under Publications. It lists the Kidney360 article on atrasentan in IgA nephropathy (online ahead of print, 2025).SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page’s revision tag was updated from v3.5.3 to v3.5.4, indicating a new release of the site framework or content management. This change reflects an internal version update rather than an alteration to the study information or visible user content.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page’s UI/version label has been updated from “Revision: v3.5.2” to “Revision: v3.5.3” without any accompanying change to the study content.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Atrasentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.